Why the ResApp (ASX:RAP) share price is falling 18% lower today

The ResApp Health Ltd (ASX: RAP) share price is sinking more than 18% lower today following the company's release of its quarterly update.

| More on:
Falling ASX share prices represented by girl falling asleep at her computer with her head in her hands

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ResApp Health Ltd (ASX: RAP) share price is sinking lower today following the company's release of its quarterly update. At the time of writing, the ResApp share price is down 18.18% to 9 cents.

Let's take a look at why shareholders are fleeing for the hills today.

What's impacting the ResApp share price?

Investors are selling down the ResApp share price following today's release of the company's quarterly figures. For the period ending 30 September, ResApp reported a worrying result to the start of the new financial year.

Receipts from customers totalled just $3,000 due to the company only receiving payments from Apple Inc (NASDAQ: AAPL) for SleepCheck downloads during June and July, not August and September. The company noted that with ResAppDx now available on select Android smartphone devices, larger revenue streams will likely follow suit.

In addition, SleepCheck is expected to be launched on the Android platform by the end of the calendar year.

Net cash used in operating activities came to $1.4 million, and the company received $1.5 million in proceeds from the exercise of options.

Research and development costs came to $377,000 for the three months, however staff expenses took a big hit at $815,000. The employee cash outflow is double that of administration and corporate costs and almost six times that of marketing costs, $317,00 and $142,000, respectively.

ResApp closed the quarter with a cash balance of $5.8 million.

Operational overview

The company touched on a number of developments that it has made over the September period. Most notably, ResApp secured a two-year service agreement with Coviu to make ResAppDx available to Coviu's telehealth customers in Australia. Furthermore, ResAppDx also launched on Phenix Health's telehealth mobile application.

ResApp's SleepCheck product was promoted in a partnership with Diabetes Queensland. The company is confident the collaboration will lead to an uptake of its SleepCheck application, providing invaluable marketing and exposure.

Towards the end of Q1, ResApp signed on a 12-month agreement with HealthEngine to integrate its booking platform with SleepCheck. The deal will allow ResApp to identify a person with sleep apnoea, and book an appointment with a health professional.

Lastly, AstraZeneca plc (NYSE: AZN) Japan will use ResApp software in a lung cancer clinical study. A new cough counting smartphone application will be trialed in a number of patients undergoing treatment for lung cancer. AstraZeneca will pay a monthly licencing fee for each person enrolled in the study, as well as monthly support fee.

Management commentary

ResApp CEO and managing director, Dr Tony Keating, commented on the achievement made in the quarter. He said:

ResApp achieved a number of key milestones during the period, which have created a strong foundation for it to leverage during the current quarter and beyond.

We have secured partnerships with two of Australia's leading telehealth platforms and will continue to work with both Phenix and Coviu to explore opportunities that will expedite the uptake of ResAppDx amongst clinicians, allowing the company to strengthen its revenue stream. 

Dr Keating went on to speak about ResApp's latest product to the market, SleepCheck. He added:

Our national marketing campaign for SleepCheck has resulted in good uptake amongst consumers. Download rates have continued to grow strongly month-by-month and we anticipate that these will increase as more aggressive marketing continues in the UK and other countries.

ResApp has retained a strong cash balance, which provides us with financial flexibility and ample runway to scale operations over the coming months.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and recommends Apple. The Motley Fool Australia has recommended Apple. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Fancy font saying top ten surrounded by gold leaf set against a dark background of glittering stars.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors sent the market higher once again today.

Read more »

A male investor sits at his desk looking at his laptop screen holding his hand to his chin pondering whether to buy Macquarie shares
Opinions

2 ASX shares I'd buy if the ASX crashes again

I think the best opportunities can be found when the market falls.

Read more »

A man holding a cup of coffee puts his thumb up and smiles while at laptop.
Share Market News

These ASX 200 stocks could rise 20% to 35%

These shares could be destined to deliver big returns over the next 12 months according to analysts.

Read more »

View of a mine site.
Broker Notes

How much upside does Macquarie tip for Deterra Royalties shares?

Deterra Royalties offers ASX investors a different way to invest in global mining.

Read more »

Rising gold share price represented by a green arrow on piles of gold block.
Gold

3 reasons to buy this surging ASX All Ords gold stock today

The ASX All Ords gold stock has doubled investors’ money in 12 months, and this leading expert forecasts more outperformance…

Read more »

Woman with $50 notes in her hand thinking, symbolising dividends.
Broker Notes

Broker reveals outlook for ASX dividend shares amid volatile market

Peter Gardner from Plato Investment Management tells ASX investors where to look for dividend income this year.

Read more »

Two colleagues at work looking at a tablet and smiling at a rising share price.
Share Gainers

Why Generation Development, Orica, Pro Medicus, and Zip shares are storming higher today

These shares are having a strong session on Thursday. But why?

Read more »

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Fallers

Why ANZ, Brainchip, Light & Wonder, and Pilbara Minerals shares are falling today

These shares are tumbling on Thursday. But why?

Read more »